Business Description
NuCana plc is a UK-based company focused on developing better cancer treatments by improving upon existing chemotherapy drugs. Using its proprietary ProTide technology, the company modifies known compounds to make them more effective at targeting and destroying cancer cells. Its two lead medicines, NUC-3373 and NUC-7738, are currently being tested in clinical trials for patients with colorectal cancer, lung cancer, and other solid tumors. Founded in 1997 and headquartered in Edinburgh, Scotland, NuCana works alongside Cardiff ProTides Ltd to identify and advance new drug candidates.
